IMR Press / FBS / Volume 5 / Issue 1 / DOI: 10.2741/S364

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Experimental advances in understanding allergic airway inflammation
Show Less
1 Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Ave, Box 8052, St. Louis, MO 63110, USA
2 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave, Box 8052, St Louis, MO 63110, USA
Academic Editor:Alexander Sasha Krupnick
Front. Biosci. (Schol Ed) 2013, 5(1), 167–180;
Published: 1 January 2013
(This article belongs to the Special Issue Lung tissue engineering)

Asthma is largely an inflammatory disease, with the development of T cell mediated inflammation in the lung following exposure to allergen or other precipitating factors. Currently, the major therapies for this disease are directed either at relief of bronchoconstriction (ie beta- agonists) or are non-specific immunomodulators (ie, corticosteroids). While much attention has been paid to factors that regulate the initiation of an inflammatory response, chronic inflammation may also be due to defects in regulatory mechanisms that limit or terminate immune responses. In this review, we explore the elements controlling both the recruitment of T cells to the lung and their function. Possibilities for future therapeutic intervention are highlighted.

T cells
Back to top